RemSleep Holdings Inc.

RemSleep Holdings Inc. develops and sells sleep-apnea-related products, including the DeltaWave CPAP interface and earlier CPAP machine offerings. The company is based in the United States and operates through its REMSleep subsidiary and related intellectual property around sleep-therapy devices.

−16 340,6 %

24,0 %

−18 062,9 %

−85,7 %

0.89

0.73

— RemSleep Holdings Inc.
%
DeltaWave CPAP interface70% Nasal-pillows style interface designed to deliver CPAP therapy for sleep apnea patients.
Legacy CPAP machines20% Earlier respiratory therapy equipment sold before the product transition.
Sleep apnea product development10% Design and development of new interfaces and related OSA treatment products.

The company sells to sleep-apnea patients through the respiratory-therapy and durable-medical-equipment channel, where...

  • CPAP usersprimary

    Buy the DeltaWave interface to improve comfort, reduce claustrophobia, and support adherence to therapy.

  • OSA patientsprimary

    Need sleep-apnea treatment devices that fit comfortably and support nightly use.

  • Durable medical equipment channelssecondary

    Distribute respiratory products to end users and influence product availability.

  • Clinical and medical partnerssecondary

    Support testing, validation, and broader acceptance of the product line.

RemSleep is a U.S.-based company, and the disclosed operating activity in the excerpts is centered on the United States...

  • •United States is the home market and operating base
  • •No country-level revenue split was disclosed in the excerpts
  • •Domestic regulatory and reimbursement access are important
  • •Distribution depends on U.S. sleep-therapy channels
  • •Future expansion would require market access and compliance

The company’s strategy is centered on commercializing the DeltaWave interface and building adoption in the sleep-apnea...

01
Commercialize DeltaWaveshort-term

The product is the core revenue opportunity and the basis for market entry.

02
Validate product performancemedium-term

Clinical evidence can improve adoption by patients, clinicians, and distributors.

03
Protect intellectual propertymedium-term

Patents help defend the design and support differentiation in a niche device market.

The company faces going-concern and financing risk because it has relied on external capital to support operations and...

critical

Liquidity and going-concern risk

The company states it has not generated sufficient cash flow and needs new funding.

Scope
Operations and product development funding
Materiality
high
high

Commercial adoption risk

Revenue depends on market acceptance of a new CPAP interface product.

Scope
DeltaWave sales
Materiality
high
medium

Clinical validation risk

Planned clinical trials may not confirm expected effectiveness or usability benefits.

Scope
Product credibility and regulatory/commercial acceptance
Materiality
medium
medium

Competitive pressure

The sleep-apnea device market includes established brands and distribution networks.

Scope
Pricing, channel access, and customer retention
Materiality
medium
Revenue recognition on product sales
Quarterly revenue can be lumpy and hard to compare period to period
Development expense capitalization vs expensing
Changes in development activity can materially alter expense trends
Going-concern disclosure
Important for assessing liquidity, valuation, and financial statement reliability

RESMED INC

RMD · Surgical & Medical Instruments & Apparatus

Sleep Cycle

SLEEP.ST · Technology

ENSIGN GROUP, INC

ENSG · Services-Skilled Nursing Care Facilities

REST EZ Inc.

Pharmaceutical Preparations

SOMNIGROUP INTERNATIONAL INC.

SGI · Household Furniture

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

: 29.4.2026